Close Menu

NEW YORK (GenomeWeb) – Fluidigm said after the close of the market on Thursday that it has formed a strategic partnership with Ascendas Genomics to develop molecular diagnostics in China.

Under the agreement, Ascendas will develop and commercialize molecular diagnostic systems and assays using microfluidic technologies included in Fluidigm's Biomark HD and Juno systems.

Fluidigm's platforms enable scalable and automated workflows for quantitative PCR, gene expression, copy number variation analysis, and next-generation sequencing library preparation.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.